Recent trends in big pharma acquisitions and biotech startups show a surge in interest in drugs developed in China, highlighting intense competition for these assets. Foresite Capital, which has been investing in Chinese innovation since 2019, has identified oncology and immunology as key areas of growth. The company's investment strategy includes establishing incubators to mature these innovations, supported by artificial intelligence to analyze genomic data. With a recent $900 million fund closure, Foresite aims to back startups across various stages and therapeutic areas, leveraging China's scientific advancements.
China is teeming with promising science in areas such as oncology and immunology, but competition for these assets has become more intense from big pharma.
Foresite has made Chinese innovation a key part of its investment strategy, utilizing AI to analyze genomic data and identify drug targets.
We do a lot of oncology, autoimmune. We have investments in neuroscience. We also do platform companies, covering a broad spectrum of therapeutic areas.
Last year, we closed our sixth fund with $900 million to invest in startups at all stages, emphasizing our commitment to nurturing innovation.
Collection
[
|
...
]